Arş. Gör. Dr. ESRA NALBAT

Yayın Ağı

Makaleler 7

1. Vicinal Diaryl-Substituted Isoxazole and Pyrazole Derivatives with in Vitro Growth Inhibitory and in Vivo Antitumor Activity

Turanll S., Nalbat E., Lengerli D., İbiş K., Güntekin Ergün S., Akhan Güzelcan E., et al.

ACS Omega , cilt.7, sa.41, ss.36206-36226, 2022 (SCI-Expanded, Scopus)

2. Data Centric Molecular Analysis and Evaluation of Hepatocellular Carcinoma Therapeutics Using Machine Intelligence-Based Tools

Cetin-Atalay R., Kahraman D. C., Nalbat E., Rifaioğlu A. S., Atakan A., Dönmez A., et al.

JOURNAL OF GASTROINTESTINAL CANCER , cilt.52, sa.4, ss.1266-1276, 2021 (ESCI, Scopus)

3. Synthesis and biological evaluation of novel isoxazole-piperazine hybrids as potential anti-cancer agents with inhibitory effect on liver cancer stem cells

Ibis K., NALBAT E., ÇALIŞKAN B., KAHRAMAN D. C., Cetin-Atalay R., BANOĞLU E.

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , cilt.221, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

4. CROssBAR: comprehensive resource of biomedical relations with knowledge graph representations.

DOĞAN T., Atas H., Joshi V., ATAKAN A., Rifaioglu A. S., NALBAT E., et al.

Nucleic acids research , cilt.49, sa.16, 2021 (SCI-Expanded, Scopus)

5. Treatment of breast cancer with autophagy inhibitory microRNAs carried by AGO2-conjugated nanoparticles.

Unal O., Akkoc Y., Kocak M., Nalbat E., Dogan-Ekici A., Yagci A., et al.

Journal of nanobiotechnology , cilt.18, ss.65, 2020 (SCI-Expanded, Scopus)

6. DEEPScreen: high performance drug-target interaction prediction with convolutional neural networks using 2-D structural compound representations

RİFAİOĞLU A. S., NALBAT E., Atalay V., Martin M. J., Cetin-Atalay R., DOĞAN T.

CHEMICAL SCIENCE , cilt.11, sa.9, ss.2531-2557, 2020 (SCI-Expanded, Scopus)

7. Synthesis and cellular bioactivities of novel isoxazole derivatives incorporating an arylpiperazine moiety as anticancer agents.

ÇALIŞKAN B., Sinoplu E., Ibis K., Guzelcan E. A., Atalay R. C., BANOĞLU E.

Journal of enzyme inhibition and medicinal chemistry , cilt.33, sa.1, ss.1352-1361, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 30

1. Comprehensive In Silico Profiling of Dual-Specificity Phosphatases in Hepatocellular Carcinoma: Novel Biomarkers and Therapeutic Targets

Nalbat E.

X. Multidisciplinary Cancer Research Congress, Eskişehir, Türkiye, 8 - 11 Mayıs 2025, ss.60, (Tam Metin Bildiri)

2. Hepatosellüler karsinomda DUSP11’in İşlevsel Profili: Bağışıklık Kaçışı ve Klinik Heterojenliğe Etkisi

NALBAT E.

16. Ulusal Karaciğer Kongresi, Ankara, Türkiye, 15 - 18 Mayıs 2025, (Özet Bildiri)

3. Unveiling Molecular Biomarkers of MASLD Fibrosis: A Transcriptomic and Pathway Enrichment Analysis

NALBAT E., KAHRAMAN D. C.

AASLD-TASL Hepatology Connect Meeting 2025, İstanbul, Türkiye, 14 - 15 Şubat 2025, (Özet Bildiri)

4. Prognostic and therapeutic insights into LTBP1 in Hepatocellular Carcinoma: pathway enrichment, immune profiling, and drug repurposing

NALBAT E., Gülhan R. U.

AASLD-TASL Hepatology Connect Meeting, İstanbul, Türkiye, 14 Şubat 2025, (Özet Bildiri)

5. Deciphering Transcriptional Landscapes of Mild and Advanced MASLD Fibrosis: Insights into Differential Gene Expression, Pathway Enrichment, and Drug Repurposing Opportunities

NALBAT E., KAHRAMAN D. C.

17th International Symposium on Health Informatics and Bioinformatics, İstanbul, Türkiye, 18 - 20 Aralık 2024, (Özet Bildiri)

6. In Silico Analysis of Latent Transforming Growth Factor β Binding Protein Family Expression Patterns and Prognostic Value in Hepatocellular Carcinoma

Gülhan R. U., Nalbat E.

17th The International Symposium on Health Informatics and Bioinformatics, İstanbul, Türkiye, 18 Aralık 2024, ss.151, (Özet Bildiri)

7. CCL2 as a Key Mediator of Neural Invasion in Tumor Progression: An In Silico Study

Yıldırım B., Nalbat E.

17th The International Symposium on Health Informatics and Bioinformatics, İstanbul, Türkiye, 18 Aralık 2024, ss.159, (Özet Bildiri)

8. Vicinal Diaryl-Substituted Compounds: Promising Therapeutics for Breast Cancer

NALBAT E., GÜNTEKİN ERGÜN S., TURANLI S., LENGERLİ D., ÇALIŞKAN B., BANOĞLU E., et al.

2024 Annual Congress of the European Association for Cancer Research (EACR 2024), Rotterdam, Hollanda, 10 - 13 Haziran 2024, (Özet Bildiri)

9. Hepatocellular Carcinoma: Evaluation of Vicinal Diaryl Isoxazole and Pyrazole Derivatives with Implications for Oxidative Stress and Senescence-mediated Anti-tumor Mechanisms

NALBAT E., AKHAN GÜZELCAN E., TURANLI S., LENGERLİ D., ÇALIŞKAN B., BANOĞLU E., et al.

EASL Liver Cancer Summit 2024, 22 - 24 Şubat 2024, (Özet Bildiri)

10. Exploring Cytotoxic Bioactivities of Newly Identified Compounds against Hepatocellular Carcinoma

Nalbat E., Akhan Güzelcan E., Turanlı S., Çalışkan B., Banoğlu E., Atalay R.

AASLD-TASL Hepatology Connect Meeting, İzmir, Türkiye, 16 - 17 Şubat 2024, ss.32-33, (Özet Bildiri)

11. Exploring early markers of fibrosis progression in metabolic dysfunction–associated steatotic liver disease in Turkiye

KAHRAMAN D. C., NALBAT E., ATALAY R., İDİLMAN R.

AASLD-TASL Connect Meeting 2024, İzmir, Türkiye, 16 - 17 Şubat 2024, (Özet Bildiri)

12. Repurposing Drugs to Target Molecular Networks in Hepatocellular Carcinoma Cells & Stem Cells for Innovative Treatment Strategies

NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.

4th Open Research Day, Türkiye, 01 Aralık 2023, (Özet Bildiri)

13. Exploring novel vicinal diaryl-substituted isoxazole and pyrazole derivatives as cytotoxic compounds for targeting breast cancer: Mechanisms and therapeutic potential

NALBAT E., GÜNTEKİN ERGÜN S., TURANLI S., LENGERLİ D., ÇALIŞKAN B., BANOĞLU E., et al.

XVIII. Tıbbi Biyoloji ve Genetik Kongresi, Ankara, Türkiye, 26 - 29 Ekim 2023, (Tam Metin Bildiri)

14. Breaking Barriers in Cancer Treatment: Unleashing the Power of Drug Repurposing

NALBAT E.

3rd International Multidisciplinary Cancer Research Congress, İstanbul, Türkiye, 7 - 09 Eylül 2023, (Özet Bildiri)

15. Network-based drug repurposing approach identifies novel drugs and drug combinations against HCC

NALBAT E., TUNÇBAĞ N., KAHRAMAN D. C., ATALAY R.

AASLD-TASL Digital Hepatology Meeting, Ankara, Türkiye, 28 - 29 Nisan 2023, (Özet Bildiri)

16. Network-based in silico modeling for drug repurposing and in vitro validation in hepatocellular carcinoma

Nalbat E., Tunçbağ N., Atalay R.

15th International Symposium on Health Informatics and Bioinformatics (HIBIT), Mersin, Türkiye, 20 - 21 Ekim 2022, ss.1-2, (Özet Bildiri)

17. Bazı Visinal Diaril Heterosiklik Bileşiklerin Antikanser Aktivitelerinin Araştırılması

TURANLI S., NALBAT E., AKHAN GÜZELCAN E., ATALAY R., ÇALIŞKAN B., BANOĞLU E.

VI.Ulusal Farmasötik Kimya Kongresi, İstanbul, Türkiye, 26 - 29 Ağustos 2022, (Tam Metin Bildiri)

18. KARACİĞER KANSERİ KÖK HÜCRELERİ ÜZERİNDE İNHİBİTÖR ETKİYE SAHİP, POTANSİYEL ANTİKANSER AJANLAR OLARAK YENİ İZOKSAZOL-PİPERAZİN HİBRİTLERİNİN SENTEZİ VE BİYOLOJİK OLARAK DEĞERLENDİRİLMESİ

İBİŞ K., NALBAT E., ÇALIŞKAN B., ATALAY R., BANOĞLU E.

VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Türkiye, 26 - 29 Ağustos 2022, (Tam Metin Bildiri)

19. Synthesis and Biological Evaluation of Novel Isoxazole-Piperazine Hybrids as Potential Anticancer Agents with Inhibitory Effects on Liver Cancer Stem Cells

İbiş K., Nalbat E., Çalışkan B., Atalay R., Banoğlu E.

VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Türkiye, 26 - 29 Ağustos 2022, ss.58-61, (Özet Bildiri)

20. BAZI VİSİNAL DİARİL HETEROSİKLİK BİLEŞİKLERİN ANTİKANSER AKTİVİTELERİNİN ARAŞTIRILMASI

Turanlı S., Nalbat E., Akhan Güzelcan E., Atalay R., Çalışkan B., Banoğlu E.

VI. Ulusal Farmasötik Kimya Kongresi, İstanbul, Türkiye, 26 - 29 Ağustos 2022, ss.40-42, (Özet Bildiri)

21. Identification of undefined off-targets of novel drugs and drug combinations with network-based in silico modeling and in vitro validation in hepatocellular carcinoma

Nalbat E., Tunçbağ N., Atalay R.

EACR 2022 Annual Meeting, Sevilla, İspanya, 20 - 23 Haziran 2022, ss.3-4, (Özet Bildiri)

22. Anticancer activity of novel vicinal diaryl isoxazole compounds in hepatocellular carcinoma

Nalbat E., Akhan Güzelcan E., Turanlı S., Lengerli D., Çalışkan B., Banoğlu E., et al.

EASL Liver Cancer Summit 2022, 3 - 04 Şubat 2022, ss.137-138, (Özet Bildiri)

23. Novel isoxazole- piperazine derivatives inhibit the stemness of HCC cells

NALBAT E., İBİŞ K., ÇALIŞKAN B., BANOĞLU E., ATALAY M. V., ATALAY R.

AASLD-TASL Digital Hepatology Meeting, Ankara, Türkiye, 15 Ocak 2022, ss.5-6, (Tam Metin Bildiri)

24. In vitro validation of drug-target interactions revealed in silico by Comprehensive Resource of Biomedical Relations with Network Representations and Deep Learning (CROssBAR) in HCC

NALBAT E., RİFAİOĞLU A. S., DOĞAN T., Martin M. J., Cetin-Atalay R., ATALAY M. V.

AACR Annual Meeting, ELECTR NETWORK, 22 - 24 Haziran 2020, cilt.80, (Özet Bildiri)

25. Synthesis of New Vicinal Diaryl Five-Membered Heterocyclic Compounds with Potential Anticancer Activity

TURANLİ S., LENGERLİ D., ÇALIŞKAN B., AKHAN GÜZELCAN E., NALBAT E., ATALAY R., et al.

8th International Drug Chemistry Conference, 27 Şubat - 01 Mart 2020, (Özet Bildiri)

26. CROssBAR: Comprehensive Resource of Biomedical Relations with Network Representations and Deep Learning”, Oral presentation

Atalay M. V., Doğan T., Atalay R., Nalbat E., Rifaioğlu A. S., Ataş H., et al.

27th Conference on Intelligent Systems for Molecular Biology and 18th European Conference on Computational Biology, Basel, İsviçre, 21 - 25 Temmuz 2019, (Yayınlanmadı)

27. In silico modeling and in vitro validation of undefined off-target of drugs in hepatocellular carcinoma

Sinoplu E., Tuncbag N., Kahraman D. C., Atalay R. C.

Annual Meeting of the American-Association-for-Cancer-Research (AACR), Georgia, Amerika Birleşik Devletleri, 29 Mart - 03 Nisan 2019, cilt.79, (Özet Bildiri)